Is there any relationship between benign endometrial pathologies and metabolic status?

Basit Öğe Kaydı
dc.authoridKaya, Başak Bilir/0000-0002-9586-9547
dc.authoridKayhan Tetik, Burcu/0000-0002-3976-4986
dc.authoridKeskin, Huseyin Levent/0000-0002-2268-3821
dc.authorwosidKaya, Başak Bilir/U-9563-2019
dc.authorwosidKayhan Tetik, Burcu/ABH-3056-2020
dc.authorwosidKeskin, H. Levent/ABD-2436-2022
dc.contributor.authorKaya, Serdar
dc.contributor.authorKaya, Basak
dc.contributor.authorKeskin, Hueseyin Levent
dc.contributor.authorTetik, Burcu Kayhan
dc.contributor.authorYavuz, Filiz Ayse
dc.date.accessioned2024-08-04T20:45:27Z
dc.date.available2024-08-04T20:45:27Z
dc.date.issued2019
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe aim of this study was to assess the relation between benign endometrial pathologies (polyp and/or hyperplasia without atypia) and the metabolic status (insulin resistance and metabolic syndrome) of the patients. A total of 168 cases were enrolled in the study. The patients were classified according to the presence of benign endometrial pathologies and their menopausal status. Then, the subjects were evaluated according to the metabolic syndrome criteria and the presence of an insulin resistance. The insulin resistance levels of the cases were analysed by four different methods. Obesity and a waist circumference of greater than 88 cm were observed significantly more in the study group with endometrial pathologies (p = .005 and p < .001, respectively). It was also observed that a fasting blood glucose level of higher than 110 mg/dL increased the risk of developing endometrial polyps and/or hyperplasia without atypia by almost five folds (OR: 5.26, 95% CI: 1.25-22.12). Furthermore, an insulin resistance was found to be significantly high in the study group (p = .002). Based on the observed significant relationship between an insulin resistance and benign endometrial pathologies, it can be concluded that insulin resistance plays an important role in the development of benign endometrial pathologies.en_US
dc.identifier.doi10.1080/01443615.2018.1469606
dc.identifier.endpage183en_US
dc.identifier.issn0144-3615
dc.identifier.issn1364-6893
dc.identifier.issue2en_US
dc.identifier.pmid30286675en_US
dc.identifier.scopus2-s2.0-85054485700en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage176en_US
dc.identifier.urihttps://doi.org/10.1080/01443615.2018.1469606
dc.identifier.urihttps://hdl.handle.net/11616/98487
dc.identifier.volume39en_US
dc.identifier.wosWOS:000458238400007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofJournal of Obstetrics and Gynaecologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEndometrial hyperplasiaen_US
dc.subjectendometrial polypen_US
dc.subjectinsulin resistanceen_US
dc.subjectmetabolic statusen_US
dc.subjectmetabolic syndromeen_US
dc.subjectobesityen_US
dc.titleIs there any relationship between benign endometrial pathologies and metabolic status?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu